Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

23andMe, Inc., a consumer genetics and research company, engages in developing a genetic database to unlock insights leading to the rapid discovery of new targets for drug development. It offers a crowdsourced platform that helps people to access, understand, and benefit from the human genome; access direct-to-consumer genetic testing; and give consumers personalized information about their genetic health risks, ancestry, and traits. The company was incorporated in 2006 and is based in Sunnyvale, California with an additional office in Mountain View, California.
Website: 23andme.com



Growth: Good revenue growth rate 17.5%, there is slowdown compared to average historical growth rates 98.4%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +5.2%

Profitability: LTM EBITDA margin is negative, -92.9%. On average the margin is improving steadily. Gross margin is high, +45.9%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -63.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 27.1% higher than minimum and 96.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 0.8x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.2 mln (-0.060% of cap.)

Key Financials (Download financials)

Ticker: ME
Share price, USD:  (+4.6%)0.5104
year average price 1.2386  


year start price 2.2500 2023-03-30

max close price 2.2900 2023-04-13

min close price 0.4015 2024-03-22

current price 0.5104 2024-03-28
Common stocks: 449 172 999

Dividend Yield:  0.0%
Last revenue growth (y/y):  17.5%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  98.4%
Historical growth of EBITDA:  0.0%
EV / Sales: -0.4x
Margin (EBITDA LTM / Revenue): -92.9%
Fundamental value created in LTM:
Market Cap ($m): 229
Net Debt ($m): -353
EV (Enterprise Value): -124
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-24The Motley Fool

Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?

2024-02-17The Guardian

‘There are no serious safeguards': can 23andMe be trusted with our DNA?

2024-02-08CNBC

23andMe considers splitting up company to revive stock price

2024-02-08Market Watch

23andMe shares slide more than 15% as lower services revenue hits Q3 results

2024-02-07Seeking Alpha

23andMe Holding Co. (ME) Q3 2024 Earnings Call Transcript

2024-02-01Business Insider

23andMe's share price keeps on falling in the wake of hacks and losses

2024-02-0124/7 Wall Street

23andMe Destroyed by Hackers and Losses

2024-01-26NYTimes

23andMe Breach Targeted Jewish and Chinese Customers, Lawsuit Says

2024-01-25TechCrunch

23andMe admits it didn't detect cyberattacks for months

2024-01-03Fox Business

23andMe blames users for data breach, citing recycled passwords
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ME ME ME ME ME ME
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-07 2023-11-08 2023-08-08 2023-05-25 2023-02-08 2022-11-07
acceptedDate 2024-02-07 16:07:48 2023-11-08 16:15:52 2023-08-08 16:16:19 2023-05-25 16:14:04 2023-02-08 16:11:59 2022-11-07 16:12:03
calendarYear 2023.000 2023.000 2023.000 2022.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 45M 50M 61M 92M 67M 76M
costOfRevenue 25M 28M 30M 52M 36M 37M
grossProfit 20M 22M 31M 40M 31M 38M
grossProfitRatio 0.446 0.435 0.504 0.433 0.459 0.506
researchAndDevelopmentExpenses 42M 55M 62M 61M 57M 53M
generalAndAdministrativeExpenses 36M 30M 55M 27M 31M 34M
sellingAndMarketingExpenses 22M 11M 15M 22M 40M 16M
sellingGeneralAndAdministrativeExpenses 57M 41M 71M 49M 71M 50M
otherExpenses 23 000 145 000 333 000 174 000 855 000 3M
operatingExpenses 101M 98M 136M 109M 128M 106M
costAndExpenses 126M 126M 166M 162M 164M 144M
interestIncome 3M 4M 4M 4M 4M 1M
interestExpense 0 0 0 -5M 1M 1M
depreciationAndAmortization 7M 8M 8M 8M 9M 9M
ebitda 127M -66M -93M -61M -97M -59M
ebitdaratio 2.831 -1.314 -1.523 -0.659 -1.451 -0.775
operatingIncome -281M -79M -109M -69M -97M -68M
operatingIncomeRatio -6.284 -1.583 -1.795 -0.750 -1.451 -0.899
totalOtherIncomeExpensesNet -200M -3M -4M 5M 5M 705 000
incomeBeforeTax -278M -75M -105M -65M -93M -67M
incomeBeforeTaxRatio -6.212 -1.505 -1.719 -0.701 -1.383 -0.890
incomeTaxExpense 19 000 36 000 -90 000 -633 000 -613 000 -1M
netIncome -278M -75M -105M -64M -92M -66M
netIncomeRatio -6.212 -1.505 -1.719 -0.694 -1.374 -0.873
eps -0.580 -0.160 -0.230 -0.140 -0.200 -0.150
epsdiluted -0.580 -0.160 -0.230 -0.140 -0.200 -0.150
weightedAverageShsOut 481M 475M 462M 456M 453M 450M
weightedAverageShsOutDil 481M 475M 462M 456M 453M 450M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ME ME ME ME ME ME
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-07 2023-11-08 2023-08-08 2023-05-25 2023-02-08 2022-11-07
acceptedDate 2024-02-07 16:07:48 2023-11-08 16:15:52 2023-08-08 16:16:19 2023-05-25 16:14:04 2023-02-08 16:11:59 2022-11-07 16:12:03
calendarYear 2023.000 2023.000 2023.000 2022.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 242M 256M 314M 387M 433M 411M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 242M 256M 314M 387M 433M 411M
netReceivables 24M 2M 4M 2M 27M 53M
inventory 16M 15M 12M 10M 12M 14M
otherCurrentAssets 3M 18M 21M 19M 21M 29M
totalCurrentAssets 310M 298M 360M 425M 509M 506M
propertyPlantEquipmentNet 81M 85M 90M 95M 91M 96M
goodwill 153M 352M 352M 352M 352M 352M
intangibleAssets 55M 57M 60M 61M 63M 76M
goodwillAndIntangibleAssets 208M 409M 411M 413M 415M 428M
longTermInvestments 7M 7M 0 0 0 0
taxAssets -7M -7M 0 0 0 0
otherNonCurrentAssets 9M 9M 10M 10M 10M 10M
totalNonCurrentAssets 298M 503M 511M 518M 516M 535M
otherAssets 0 0 0 0 0 0
totalAssets 608M 801M 871M 943M 1 025M 1 041M
accountPayables 13M 9M 13M 13M 14M 11M
shortTermDebt 8M 8M 8M 8M 8M 8M
taxPayables 1M 873 000 1M 1M 2M 1M
deferredRevenue 80M 40M 48M 63M 109M 82M
otherCurrentLiabilities 42M 45M 50M 66M 69M 44M
totalCurrentLiabilities 144M 102M 119M 149M 200M 145M
longTermDebt 70M 73M 75M 78M 71M 74M
deferredRevenueNonCurrent 15M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 1M 1M 1M 1M 2M -24M
totalNonCurrentLiabilities 87M 74M 77M 79M 74M 77M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 79M 81M 83M 85M 80M 82M
totalLiabilities 231M 176M 196M 229M 274M 221M
preferredStock 0 0 0 0 0 0
commonStock 48 000 48 000 47 000 46 000 45 000 45 000
retainedEarnings -1 964M -1 686M -1 611M -1 506M -1 442M -1 350M
accumulatedOtherComprehensiveIncomeLoss 0 0 -954 000 -620 000 -311 000 2M
othertotalStockholdersEquity 2 341M 2 311M 2 287M 2 221M 2 194M 2 168M
totalStockholdersEquity 377M 625M 675M 714M 751M 819M
totalEquity 377M 625M 675M 714M 751M 819M
totalLiabilitiesAndStockholdersEquity 608M 801M 871M 943M 1 025M 1 041M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 608M 801M 871M 943M 1 025M 1 041M
totalInvestments 7M 7M 0 0 0 0
totalDebt 79M 81M 83M 85M 80M 82M
netDebt -164M -175M -231M -302M -353M -329M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ME ME ME ME ME ME
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-07 2023-11-08 2023-08-08 2023-05-25 2023-02-08 2022-11-07
acceptedDate 2024-02-07 16:07:48 2023-11-08 16:15:52 2023-08-08 16:16:19 2023-05-25 16:14:04 2023-02-08 16:11:59 2022-11-07 16:12:03
calendarYear 2023.000 2023.000 2023.000 2022.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -278M -75M -105M -64M -92M -66M
depreciationAndAmortization 7M 8M 8M 8M 9M 9M
deferredIncomeTax 19 000 36 000 23M -633 000 -4M -1M
stockBasedCompensation 26M 24M 51M 22M 34M 29M
changeInWorkingCapital 33M -15M -24M -12M 64M -45M
accountsReceivables -17M 3M -2M 25M 26M -50M
inventory -687 000 -3M -2M 2M 2M -2M
accountsPayables 5M -4M -2000.000 -1M 4M -8M
otherWorkingCapital 46M -11M -20M -37M 32M 15M
otherNonCashItems 199M 1M -23M 711 000 14M 1M
netCashProvidedByOperatingActivities -12M -57M -69M -45M 26M -73M
investmentsInPropertyPlantAndEquipment -2M -3M -3M -3M -3M -2M
acquisitionsNet 1000.000 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 5000.000 0 -2000.000 2000.000
netCashUsedForInvestingActivites -2M -3M -3M -3M -3M -2M
debtRepayment 0 0 0 0 0 0
commonStockIssued 121 000 2M 0 -2M 0 0
commonStockRepurchased -16 000 -21 000 0 6M 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 0 -114 000 -2M -11 000 6M
netCashUsedProvidedByFinancingActivities 105 000 2M -114 000 3M -11 000 6M
effectOfForexChangesOnCash 0 334 000 -334 000 -309 000 -758 000 829 000
netChangeInCash -14M -58M -72M -46M 22M -69M
cashAtEndOfPeriod 251M 265M 323M 395M 441M 419M
cashAtBeginningOfPeriod 265M 323M 395M 441M 419M 488M
operatingCashFlow -12M -57M -69M -45M 26M -73M
capitalExpenditure -2M -3M -3M -3M -3M -2M
freeCashFlow -14M -60M -72M -48M 22M -75M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2023-02-08 ET (fiscal 2023 q3)
2023 q3
2022-11-07 ET (fiscal 2023 q2)
2023 q2
2022-08-08 ET (fiscal 2023 q1)
2023 q1
2022-05-26 ET (fiscal 2022 q4)
2022 q4
2022-02-10 ET (fiscal 2022 q3)
2022 q2
2021-08-13 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-07 21:01 ET
23andMe Reports Third Quarter Fiscal 2024 Financial Results
2024-01-31 12:30 ET
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
2024-01-31 03:12 ET
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
2024-01-24 21:05 ET
23andMe to Report FY2024 Third Quarter Financial Results
2023-12-19 13:00 ET
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
2023-11-13 22:30 ET
PRIVACY ALERT: Genetic Testing Company 23andMe Faces Class Action Investigation for Cyberattack Potentially Impacting Five Million Customers
2023-11-08 21:05 ET
23andMe Reports Second Quarter Fiscal 2024 Financial Results
2023-11-07 13:00 ET
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
2023-11-06 13:00 ET
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
2023-10-31 12:00 ET
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
2023-10-30 12:00 ET
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
2023-10-25 20:05 ET
23andMe to Report FY2024 Second Quarter Financial Results
2023-09-27 20:05 ET
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
2023-09-14 11:00 ET
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
2023-08-31 21:28 ET
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
2023-08-08 20:05 ET
23andMe Reports FY2024 First Quarter Financial Results
2023-07-25 20:05 ET
23andMe to Report FY2024 First Quarter Financial Results
2023-07-20 13:23 ET
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
2023-06-21 11:00 ET
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
2023-05-25 20:05 ET
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
2023-05-16 11:00 ET
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
2023-05-11 20:05 ET
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
2023-05-09 11:00 ET
23andMe Releases New Report Revealing Likelihood of Developing Lupus
2023-05-08 11:00 ET
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
2023-04-14 20:05 ET
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
2023-04-11 11:00 ET
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
2023-03-29 11:01 ET
23andMe Publishes Inaugural Environmental, Social and Governance Report
2023-03-24 11:00 ET
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
2023-03-14 20:30 ET
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
2023-03-09 14:00 ET
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
2023-02-28 12:00 ET
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
2023-02-22 21:05 ET
23andMe to Present at Upcoming Investor Conferences
2023-02-08 21:05 ET
23andMe Reports FY2023 Third Quarter Financial Results
2023-01-26 21:05 ET
23andMe to Report FY2023 Third Quarter Financial Results
2022-12-01 17:00 ET
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
2022-11-07 21:01 ET
23andMe Reports FY2023 Second Quarter Financial Results
2022-11-07 13:00 ET
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
2022-10-27 10:45 ET
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
2022-10-24 20:05 ET
23andMe to Report FY2023 Second Quarter Financial Results
2022-10-12 20:10 ET
23andMe to Present at Upcoming Investor Conferences
2022-10-05 12:21 ET
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
2022-09-19 10:45 ET
Daniel Chu Joins 23andMe as Chief Product Officer
2022-08-08 20:05 ET
23andMe Reports FY2023 First Quarter Financial Results
2022-07-25 20:05 ET
23andMe to Report FY2023 First Quarter Financial Results
2022-05-26 20:05 ET
23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results
2022-05-12 20:10 ET
23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
2022-03-15 10:45 ET
23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-02-25 13:30 ET
23andMe to Present at Cowen 42nd Annual Health Care Conference
2022-02-17 14:00 ET
23andMe to Present at Citi’s 2022 Virtual Healthcare Conference
2022-02-10 21:04 ET
23andMe Reports FY2022 Third Quarter Financial Results
2022-01-27 21:05 ET
23andMe to Report FY2022 Third Quarter Financial Results
2022-01-18 11:55 ET
23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
2022-01-10 13:00 ET
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
2022-01-06 14:00 ET
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
2021-12-28 21:05 ET
23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants
2021-11-30 14:15 ET
23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer
2021-11-22 21:15 ET
23andMe Announces Redemption of All Outstanding Warrants
2021-11-10 21:05 ET
23andMe Reports FY2022 Second Quarter Financial Results
2021-11-09 21:30 ET
23andMe to Present at Upcoming Virtual Healthcare Conferences
2021-11-09 14:00 ET
23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors
2021-11-03 20:30 ET
23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders
2021-11-01 20:05 ET
23andMe Announces the Closing of its Acquisition of Lemonaid Health
2021-10-22 10:55 ET
23andMe Agrees to Acquire Lemonaid Health
2021-10-20 22:30 ET
23andMe to Report FY2022 Second Quarter Financial Results on November 10, 2021
2021-09-01 20:05 ET
23andMe to Present at the Wells Fargo Healthcare Conference
2021-08-13 11:00 ET
23andMe Reports FY2022 First Quarter Financial Results
2021-07-29 11:00 ET
23andMe to Report FY2022 First Quarter Financial Results
2021-06-21 12:00 ET
Industry Leaders Join 23andMe Board of Directors

SEC forms

Show financial reports only

SEC form 10
2024-02-07 00:00 ET
23andMe reported for 2023 q4
SEC form 8
2024-02-07 00:00 ET
23andMe published news for 2023 q4
SEC form 8
2024-02-07 00:00 ET
23andMe reported for 2023 q4
SEC form 8
2023-11-08 16:29 ET
23andMe reported for 2023 q3
SEC form 10
2023-11-08 16:15 ET
23andMe reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
23andMe reported for 2023 q3
SEC form 10
2023-08-08 16:16 ET
23andMe reported for 2023 q2
SEC form 6
2023-08-08 16:10 ET
23andMe reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
23andMe reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
23andMe reported for 2023 q2
SEC form 6
2023-07-26 16:05 ET
23andMe published news for 2023 q2
SEC form 6
2023-06-09 16:05 ET
23andMe published news for 2023 q1
SEC form 10
2023-05-25 16:14 ET
23andMe reported for 2023 q1
SEC form 6
2023-05-25 16:08 ET
23andMe reported for 2023 q1
SEC form 10
2023-05-25 00:00 ET
23andMe reported for 2023 q1
SEC form 8
2023-05-25 00:00 ET
23andMe reported for 2023 q1
SEC form 6
2023-04-17 16:10 ET
23andMe published news for 2023 q1
SEC form 6
2023-04-14 16:08 ET
23andMe published news for 2023 q1
SEC form 10
2023-02-08 16:11 ET
23andMe reported for 2022 q4
SEC form 6
2023-02-08 16:09 ET
23andMe published news for 2022 q4
SEC form 8
2023-02-08 00:00 ET
23andMe reported for 2022 q4
SEC form 10
2023-02-08 00:00 ET
23andMe published news for 2022 q4
SEC form 6
2023-02-06 16:53 ET
23andMe published news for 2022 q4
SEC form 6
2022-12-09 08:05 ET
23andMe published news for 2022 q3
SEC form 6
2022-11-09 07:30 ET
23andMe published news for 2022 q3
SEC form 10
2022-11-07 16:12 ET
23andMe reported for 2022 q3
SEC form 6
2022-11-07 16:06 ET
23andMe published news for 2022 q3
SEC form 8
2022-11-07 00:00 ET
23andMe reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
23andMe reported for 2022 q3
SEC form 6
2022-11-04 16:06 ET
23andMe published news for 2022 q3
SEC form 6
2022-10-27 07:32 ET
23andMe published news for 2022 q3
SEC form 6
2022-08-31 19:13 ET
23andMe published news for 2022 q2
SEC form 6
2022-08-30 16:05 ET
23andMe published news for 2022 q2
SEC form 6
2022-08-19 08:02 ET
23andMe published news for 2022 q2
SEC form 6
2022-08-18 16:06 ET
23andMe published news for 2022 q2
SEC form 6
2022-08-09 16:22 ET
23andMe published news for 2022 q2
SEC form 10
2022-08-09 16:19 ET
23andMe reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
23andMe reported for 2022 q2
SEC form 6
2022-08-08 16:14 ET
23andMe published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
23andMe reported for 2022 q2
SEC form 6
2022-07-15 08:05 ET
23andMe published news for 2022 q2
SEC form 6
2022-06-13 16:05 ET
23andMe published news for 2022 q1
SEC form 10
2022-05-27 16:03 ET
23andMe reported for 2022 q1
SEC form 10
2022-05-27 00:00 ET
23andMe reported for 2022 q1
SEC form 6
2022-05-26 16:02 ET
23andMe published news for 2022 q1
SEC form 8
2022-05-26 00:00 ET
23andMe reported for 2022 q1
SEC form 6
2022-04-13 16:57 ET
23andMe published news for 2022 q1
SEC form 6
2022-02-23 09:31 ET
23andMe published news for 2021 q4
SEC form 10
2022-02-11 13:45 ET
23andMe published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
23andMe published news for 2021 q4
SEC form 6
2022-02-10 16:11 ET
23andMe published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
23andMe published news for 2021 q4
SEC form 6
2022-01-18 08:15 ET
23andMe published news for 2021 q4
SEC form 6
2022-01-10 08:16 ET
23andMe published news for 2021 q4
SEC form 6
2022-01-06 16:05 ET
23andMe published news for 2021 q4
SEC form 6
2021-12-28 16:16 ET
23andMe published news for 2021 q3
SEC form 6
2021-11-22 16:31 ET
23andMe published news for 2021 q3
SEC form 10
2021-11-10 16:21 ET
23andMe published news for 2021 q3
SEC form 6
2021-11-10 16:11 ET
23andMe published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
23andMe published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
23andMe published news for 2021 q3
SEC form 6
2021-11-09 16:06 ET
23andMe published news for 2021 q3
SEC form 6
2021-11-02 08:02 ET
23andMe published news for 2021 q3
SEC form 6
2021-10-22 16:05 ET
23andMe published news for 2021 q3
SEC form 6
2021-09-10 07:02 ET
23andMe published news for 2021 q2
SEC form 10
2021-08-13 10:52 ET
23andMe published news for 2021 q2
SEC form 6
2021-08-13 07:13 ET
23andMe published news for 2021 q2
SEC form 8
2021-08-13 00:00 ET
23andMe published news for 2021 q2
SEC form 10
2021-08-13 00:00 ET
23andMe published news for 2021 q2
SEC form 6
2021-07-02 18:25 ET
23andMe published news for 2021 q2
SEC form 6
2021-06-25 17:36 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:35 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:27 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:24 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:24 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:22 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:22 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:21 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:20 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:19 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:18 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-25 17:16 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-21 08:32 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-21 08:31 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-11 17:28 ET
23andMe published news for 2021 q1
SEC form 6
2021-06-04 17:06 ET
23andMe published news for 2021 q1
SEC form 10
2021-06-03 13:31 ET
23andMe published news for 2021 q1
SEC form 10
2021-06-03 00:00 ET
23andMe published news for 2021 q1
SEC form 6
2021-05-28 17:15 ET
23andMe published news for 2021 q1
SEC form 6
2021-05-26 19:30 ET
23andMe published news for 2021 q1
SEC form 6
2021-05-17 16:14 ET
23andMe published news for 2021 q1
SEC form 6
2021-05-04 17:03 ET
23andMe published news for 2021 q1
SEC form 6
2021-05-03 17:23 ET
23andMe published news for 2021 q1
SEC form 6
2021-04-05 20:37 ET
23andMe published news for 2021 q1
SEC form 6
2021-03-30 17:25 ET
23andMe published news for 2020 q4
SEC form 10
2021-03-24 17:21 ET
23andMe published news for 2020 q4
SEC form 6
2021-02-16 16:19 ET
23andMe published news for 2020 q4
SEC form 6
2021-02-04 08:45 ET
23andMe published news for 2020 q4
SEC form 6
2020-11-20 16:15 ET
23andMe published news for 2020 q3
SEC form 10
2020-11-16 16:01 ET
23andMe published news for 2020 q3
SEC form 6
2020-10-22 16:18 ET
23andMe published news for 2020 q3
SEC form 6
2020-10-13 16:11 ET
23andMe published news for 2020 q3
SEC form 6
2020-10-06 16:31 ET
23andMe published news for 2020 q3
SEC form 6
2020-10-01 21:42 ET
23andMe published news for 2020 q3
SEC form 6
2020-10-01 21:41 ET
23andMe published news for 2020 q3
SEC form 6
2020-10-01 21:40 ET
23andMe published news for 2020 q3
SEC form 6
2020-10-01 21:40 ET
23andMe published news for 2020 q3
SEC form 6
2020-10-01 21:39 ET
23andMe published news for 2020 q3
SEC form 6
2020-10-01 21:39 ET
23andMe published news for 2020 q3